← all works
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Psoriasis: Treatment and Pathogenesis
- Field
- Immunology and Microbiology
- Canadian institutions
- Probity Medical ResearchWestern University
- Funders
- —
- Keywords
- UstekinumabMedicinePsoriasisPsoriasis Area and Severity IndexPlaceboClinical endpointInternal medicineRandomizationRandomized controlled trialIntention-to-treat analysisGastroenterologyDermatologyTumor necrosis factor alphaPathology
- Has abstract in OpenAlex
- no